Targeted therapy for lung cancer is playing an increasingly important role in the treatment of lung cancer. Compared with targeted drugs for other malignant tumors, there are more varieties of targeted drugs for lung cancer, and there are three generations of targeted drugs so far. For lung cancer treatment, since most of the targeted drugs are imported drugs and are not covered by medical insurance, their prices may be relatively high. The first generation of targeted drugs for lung cancer include Erlotinib and Gefitinib, as well as Kemetina, which are relatively inexpensive, costing about RMB 5,000-7,000 per month. The second-generation targeted drugs are mainly avatinib, which costs about $10,000 per month. The third-generation targeted drug is Ocitinib, also known as 9291, which is the latest generation of targeted drugs and costs more than the first and second generation, about $50,000-60,000 per month. For general lung cancer treatment, the first-generation erlotinib and gefitinib are still preferred, and these two drugs can be reimbursed in some areas and some hospitals. Only when the first generation targeted drugs fail and the disease progresses, we will consider taking the third generation of oseltinib treatment. With the reform of the national medical policy, targeted drugs are gradually included in the scope of medical insurance, and the price of targeted drugs may not be as high as it is now, so ordinary families can afford it.